An observational study in Psoriatic Arthritis, Psoriasis and Psoriatic Conditions, sponsored by Sage Bionetworks. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by Sage Bionetworks · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 194 studies in Arthritis, Psoriatic with a site in United States — 30 open to participants now, 60 under way, 20 of them phase 3. Arthritis, Psoriatic · United States.
Among the 194 studies in Arthritis, Psoriatic with a site in United States, this one is the 11th largest by planned enrollment of the 34 observational ones that give a count, is one of 11 that started in 2022, is one of 35 observational ones, reaches primary completion later than 21 of the 59 other live ones, and was the 147th registered.
602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →30 of the 194 studies in Arthritis, Psoriatic with a site in United States are open now. Recruiting first, the newest first:
Amgen · Sites in United States
Ages 18–60 · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–65
Medical College of Wisconsin · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 89 Arthritis, Psoriatic studies recruiting now, 52 (58%) set no upper age limit and 28 (31%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
194 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 35 · Phase 3 73 · Phase 4 18
First in 1991; this study’s year is marked. 11 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 280 across 244 observational studies indexed under Arthritis, Psoriatic.
Median enrollment 228 across the 159 interventional studies, 325 across the 34 observational. Of the 128 that completed or were terminated, 79 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
130 of 194 have an industry lead sponsor. The 10 most frequent:
Sage Bionetworks is the lead sponsor of 2 studies on the registry; none are open to participants now.
Sage Bionetworks has 1 study filed under Arthritis, Psoriatic — fewer than ten, so there is no comparison to draw.
17 of the studies in Arthritis, Psoriatic with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641089Phase 3MoonLake Immunotherapeutics AGEvaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | 2027-01-04 |
| NCT06807424Phase 3Janssen Research & Development, LLCA Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis | 2027-02-10 |
| NCT06506916Phase 3UCB Biopharma SRLA Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis | 2027-03-09 |
| NCT06671483Phase 3TakedaA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | 2027-05-18 |
| NCT06671496Phase 3TakedaA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines | 2027-05-18 |
Add all 17 to your calendar (.ics) → With an account.
Among the 194 studies in Arthritis, Psoriatic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to understand variation in the symptoms of psoriasis and psoriatic arthritis using simple, scalable smartphone-based measurements. This study uses an iPhone app to record these symptoms through questionnaires and sensors.
Psoriatic disease exhibits a spectrum of symptoms and can transition from psoriasis (PsO), largely affecting the skin, to psoriatic arthritis (PsA) involving widespread musculoskeletal inflammation. Early detection of the PsO-to-PsA transition and rapid administration of effective treatment is essential, as a delay in diagnosing PsA by as little as 6 months can lead to irreversible joint damage. This "ticking clock" paradigm drives the need for frequent monitoring and effective therapeutic intervention as early as possible to attenuate or possibly prevent disease progression. Using a suite of smartphone-based measurements in an app called Psorcast (psoriasis forecasts), we aim to aggregate weekly, symptom measurements from participants in a remote, longitudinal observational study to map the trajectories of treatment response and disease progression. In this study, we will explore measurements of psoriatic disease activity at least an order of magnitude more frequently (weekly vs. quarterly) than standard clinical practice or clinical trial designs. This study is not meant to provide a medical diagnosis, treatment, or medical advice. It is meant to provide a scalable, inexpensive, non-invasive and frequent measure and tracking of psoriasis and psoriatic arthritis for research purposes.
Adults with a compatible iPhone or iPod Touch who consent to particpate
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
People who report a diagnosis of Psoriasis. Participants are invited via the Psorcast mobile application to complete the following assessments: Participant self-assessment surveys, skin assessments (Psoriasis Area Draw and Psoriasis Area Photo) and musculoskeletal assessments (Finger/Toe Photos, Joint Count, Digital Jar Open, 30s Walk).
Behavioral: Participant self-assessment surveys · Behavioral: Psoriasis Draw · Behavioral: Psoriasis Area Photo · Behavioral: Finger and Toe Photos · Behavioral: Digital Jar Open · Behavioral: 30 Second Walk · Other: Psorcast mobile application
People who report a diagnosis of Psoriatic Arthritis. Participants are invited via the Psorcast mobile application to complete the following assessments: Participant self-assessment surveys, skin assessments (Psoriasis Area Draw and Psoriasis Area Photo) and musculoskeletal assessments (Finger/Toe Photos, Joint Count, Digital Jar Open, 30s Walk).
Behavioral: Participant self-assessment surveys · Behavioral: Psoriasis Draw · Behavioral: Psoriasis Area Photo · Behavioral: Finger and Toe Photos · Behavioral: Digital Jar Open · Behavioral: 30 Second Walk · Other: Psorcast mobile application
People who report no prior diagnosis of Psoriasis or Psoriatic Arthritis. Participants are invited via the Psorcast mobile application to complete the following assessments: Participant self-assessment surveys, skin assessments (Psoriasis Area Draw and Psoriasis Area Photo) and musculoskeletal assessments (Finger/Toe Photos, Joint Count, Digital Jar Open, 30s Walk).
Behavioral: Participant self-assessment surveys · Behavioral: Psoriasis Draw · Behavioral: Psoriasis Area Photo · Behavioral: Finger and Toe Photos · Behavioral: Digital Jar Open · Behavioral: 30 Second Walk · Other: Psorcast mobile application
At enrollment, participants are asked to complete a baseline health history, family history, and a participant-reported symptom inventory.
Participants are asked to draw the location and size of psoriasis they currently experience. Participants are provided a body template onto which they can draw on their screen. Investigators estimate the percentage of body area affected.
Participants are asked to take a picture of a representative psoriasis plaque and indicate the location of the plaque. They are asked to take a picture of the same area over time. The investigators are developing computer vision algorithms to assess the plaque.
Participants are asked to take pictures of the back of each hand and the top of each foot. These photos can be used to assess finger and toe swelling as well as psoriatic nail involvement. The investigators are developing computer vision algorithms to assess psoriatic nail involvement and digit swelling.
Participants are asked to internally and externally rotate the phone as it rests on a flat surface. Participants perform each direction (internal and external) and each arm (left and right) in turn. Gyroscope sensors measure the degree of rotation.
Participants are asked to walk in a straight line for 30 seconds. Gait is measured by gyroscope and accelerometer sensors. The investigators examine step-dependent and sequence-dependent features from these sensors. The investigators apply feature selection and classifier algorithms to analyze these data.
Participants complete all described behavioral interventions via a dedicated iPhone app, Psorcast.
Results of participant self-assessment surveys
Results of participant self-assessment surveys will be analyzed using descriptive statistics. These results may also be compared with other intervention results.
Time frame: Through study completion, an average of 2 years
Body surface area and location from the Psoriasis Draw assessment
The investigators will quantify body surface area and psoriasis area hotspots across the cohort. These results may also be compared with other intervention results.
Time frame: Through study completion, an average of 2 years
Computer vision features from Psoriasis Area Photo assessment
The investigators apply visual processing and classifier algorithms to analyze the images from the Psoriasis Area Photo assessments. These results may also be compared with other intervention results.
Time frame: Through study completion, an average of 2 years
Computer vision features from Finger/Toe Photos
The investigators apply visual processing and classifier algorithms to segment nails and joints from hand and foot photos. These results may also be compared with other intervention results.
Time frame: Through study completion, an average of 2 years
Gyroscope and accelerometer sensor measurements from Digital Jar Open assessment
The investigators examine rotational features from gyroscope and accelerometer sensors. The investigators apply feature selection and classifier algorithms to analyze these data. These results may also be compared with other intervention results.
Time frame: Through study completion, an average of 2 years
Gyroscope and accelerometer sensor measurements from 30-sec Walk assessment
The investigators examine step-dependent and sequence-dependent features from gyroscope and accelerometer sensors. The investigators apply feature selection and classifier algorithms to analyze these data. These results may also be compared with other intervention results.
Time frame: Through study completion, an average of 2 years
Quantification and distribution of self-reported painful joints
The investigators will quantify the self-reported painful joints and, in particular, compare to measurements from the 30-sec Walk and Digital Jar Open to identify correlations. These results may also be compared with other intervention results.
Time frame: Through study completion, an average of 2 years
App usage data for assessment of participant engagement
App usage data is used to gauge participant engagement throughout the study period. These results may also be compared with other intervention results.
Time frame: Through study completion, an average of 2 years
Plan to share: Yes — We will share the de-identified data from participants who opt-in to data sharing during enrollment and consent.
Supporting information: Analytic code
Started Jan 2022 (actual). Primary completion is estimated for Jan 2027, 60 months after the start.
Of 77 non-industry observational studies under Arthritis, Psoriatic, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 20. This study's planned 60 months is above that.
Counting every sponsor, half of 129 studies reached it within 47 months; a quarter within 28 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sage Bionetworks